ArticleGynecologic oncology reports2025
Non-islet cell tumor hypoglycemia (NICTH) as a rare paraneoplastic syndrome in high-grade serous ovarian carcinoma: A case report and review of the literature.
Article in Gynecologic oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Non-islet cell tumor hypoglycemia (NICTH) is a rare paraneoplastic syndrome caused by excessive secretion of incompletely processed insulin-like growth factor-2 (IGF-2) from tumor cells. This leads to severe, refractory hypoglycemia. Case Presentation: A 67-year-old woman presented with stage IIIC high-grade ovarian carcinoma associated with severe hypoglycemia at diagnosis, and at recurrence. Laboratory tests showed suppressed insulin and C-peptide levels, with an elevated IGF-2/IGF-1 ratio, consistent with NICTH. The patient underwent primary surgery followed by adjuvant platinum-based chemotherapy and maintenance therapy with bevacizumab and olaparib. This comprehensive treatment approach led to remission of both the carcinoma and the associated severe paraneoplastic hypoglycemia. The relapse of the disease was accompanied by a recurrence of hypoglycemia, refractory to medical treatement, which ultimately led to the patient's death. Conclusion: This represents the first reported case of HGSOC with NICTH, emphasizing the complexity of ovarian cancer presentations and the importance of early diagnosis and comprehensive management in rare paraneoplastic conditions.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.